Cargando…
Phenothiazines Inhibit SARS-CoV-2 Entry through Targeting Spike Protein
Novel coronavirus disease 2019 (COVID-19), a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought an unprecedented public health crisis and continues to threaten humanity due to the persistent emergence of new variants. Therefore, developing more ef...
Autores principales: | Liang, Taizhen, Xiao, Shiqi, Wu, Ziyao, Lv, Xi, Liu, Sen, Hu, Meilin, Li, Guojie, Li, Peiwen, Ma, Xiancai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458444/ https://www.ncbi.nlm.nih.gov/pubmed/37632009 http://dx.doi.org/10.3390/v15081666 |
Ejemplares similares
-
Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1
por: Hashizume, Mei, et al.
Publicado: (2023) -
The Involvement of Ubiquitination and SUMOylation in Retroviruses Infection and Latency
por: Liang, Taizhen, et al.
Publicado: (2023) -
Targeting Spike Glycans to Inhibit SARS-CoV2 Viral Entry
por: Guseman, Alex J., et al.
Publicado: (2022) -
Targeting spike glycans to inhibit SARS-CoV2 viral entry
por: Guseman, Alex J., et al.
Publicado: (2023) -
Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2
por: Ge, Shuai, et al.
Publicado: (2021)